Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63


Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.

Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, Wallmark JM, Keam B, Delord JP, Aggarwal R, Gould M, Yang P, Keefe SM, Piha-Paul SA.

Ann Oncol. 2018 Jul 9. doi: 10.1093/annonc/mdy232. [Epub ahead of print]


Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.

Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI, Larkin J, Pal SK, Powles T, Ryan CW, Sternberg CN, Uzzo R, Choueiri TK, Bex A.

Eur Urol. 2018 May 18. pii: S0302-2838(18)30349-X. doi: 10.1016/j.eururo.2018.05.002. [Epub ahead of print] Review.


Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma.

Catino AB, Hubbard RA, Chirinos JA, Townsend R, Keefe S, Haas NB, Puzanov I, Fang JC, Agarwal N, Hyman D, Smith AM, Gordon M, Plappert T, Englefield V, Narayan V, Ewer S, ElAmm C, Lenihan D, Ky B.

Circ Heart Fail. 2018 Mar;11(3):e004408. doi: 10.1161/CIRCHEARTFAILURE.117.004408.


Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM.

J Clin Oncol. 2018 May 20;36(15):1498-1504. doi: 10.1200/JCO.2017.76.4126. Epub 2018 Apr 6.


Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.

Buti S, Puligandla M, Bersanelli M, DiPaola RS, Manola J, Taguchi S, Haas NB.

Ann Oncol. 2018 Jul 1;29(7):1604. doi: 10.1093/annonc/mdx799. No abstract available.


Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805.

Estabrook R, Cella D, Zhao F, Manola J, DiPaola RS, Wagner LI, Haas NB.

Qual Life Res. 2018 Jun;27(6):1589-1597. doi: 10.1007/s11136-018-1817-4. Epub 2018 Mar 5.


Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.

Sternberg CN, Donskov F, Haas NB, Doehn C, Russo P, Elmeliegy M, Baneyx G, Banerjee H, Aimone P, Motzer RJ.

Clin Cancer Res. 2018 Jul 1;24(13):3005-3013. doi: 10.1158/1078-0432.CCR-17-2652. Epub 2018 Jan 12.


Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.

Jilaveanu LB, Puligandla M, Weiss SA, Wang XV, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas NB, Kluger HM.

Clin Cancer Res. 2018 Jan 1;24(1):217-223. doi: 10.1158/1078-0432.CCR-17-1555. Epub 2017 Oct 24.


A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.

Yam C, Xu X, Davies MA, Gimotty PA, Morrissette JJD, Tetzlaff MT, Wani KM, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas NB, Kudchadkar RR, Pavlick AC, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC.

Clin Cancer Res. 2018 Jan 1;24(1):22-32. doi: 10.1158/1078-0432.CCR-17-1807. Epub 2017 Oct 19.


Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapies.

Subramanian P, Haas NB.

Urol Oncol. 2018 Jan;36(1):23-30. doi: 10.1016/j.urolonc.2017.09.008. Epub 2017 Oct 16. Review.


A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, Rha SY, Vaishampayan U, Harris WB, Richey S, Randall JM, Shaffer D, Cohn A, Crowell T, Li J, Senderowicz A, Stone E, Figlin R, Motzer RJ, Haas NB, Hutson T.

Ann Oncol. 2017 Nov 1;28(11):2754-2760. doi: 10.1093/annonc/mdx493.


Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.

Buti S, Puligandla M, Bersanelli M, DiPaola RS, Manola J, Taguchi S, Haas NB.

Ann Oncol. 2017 Nov 1;28(11):2747-2753. doi: 10.1093/annonc/mdx492.


Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators.

J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.


Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.

Ristau BT, Manola J, Haas NB, Heng DYC, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG.

J Urol. 2018 Jan;199(1):53-59. doi: 10.1016/j.juro.2017.07.042. Epub 2017 Jul 18.


Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.

Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, McGregor BA, Jones J, Lanman RB, Banks KC, Choueiri TK.

Eur Urol. 2017 Oct;72(4):557-564. doi: 10.1016/j.eururo.2017.03.046. Epub 2017 Apr 14.


Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.

Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK.

JAMA Oncol. 2017 Sep 1;3(9):1249-1252. doi: 10.1001/jamaoncol.2017.0076.


Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy.

Narayan V, Vapiwala N, Mick R, Subramanian P, Christodouleas JP, Bekelman JE, Deville C, Rajendran R, Haas NB.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):355-361. doi: 10.1016/j.ijrobp.2016.10.013. Epub 2016 Oct 20.


Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.

Keefe SM, Hoffman-Censits J, Cohen RB, Mamtani R, Heitjan D, Eliasof S, Nixon A, Turnbull B, Garmey EG, Gunnarsson O, Waliki M, Ciconte J, Jayaraman L, Senderowicz A, Tellez AB, Hennessy M, Piscitelli A, Vaughn D, Smith A, Haas NB.

Ann Oncol. 2016 Aug;27(8):1579-85. doi: 10.1093/annonc/mdw188. Epub 2016 Jun 8.


Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives.

Narayan V, Haas NB.

Int J Nephrol Renovasc Dis. 2016 Mar 29;9:65-72. doi: 10.2147/IJNRD.S83874. eCollection 2016. Review.


Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS.

Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9. Erratum in: Lancet. 2016 May 14;387(10032):1998.


Surveillance for Renal Cell Cancer Recurrence: Which Patients Should Undergo Imaging, How Often, and When?

Haas NB.

J Clin Oncol. 2015 Dec 10;33(35):4131-3. doi: 10.1200/JCO.2015.63.5953. Epub 2015 Oct 12. No abstract available.


Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.

Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB, Dutcher JJ, Wilding G, DiPaola RS.

Clin Cancer Res. 2015 Sep 15;21(18):4048-54. doi: 10.1158/1078-0432.CCR-15-0215. Epub 2015 May 12.


Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.

Joshua AM, Shore ND, Saad F, Chi KN, Olsson CA, Emmenegger U, Scholz M, Berry W, Mukherjee SD, Winquist E, Haas NB, Foley MA, Dmuchowski C, Perabo F, Hirmand M, Hasabou N, Rathkopf D; Enzalutamide Expanded Access Study Investigators.

Prostate. 2015 Jun;75(8):836-44. doi: 10.1002/pros.22965. Epub 2015 Feb 14.


Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI.

J Clin Oncol. 2014 Oct 20;32(30):3391-9. doi: 10.1200/JCO.2013.54.5954. Epub 2014 Sep 15.


Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation.

Lee JV, Carrer A, Shah S, Snyder NW, Wei S, Venneti S, Worth AJ, Yuan ZF, Lim HW, Liu S, Jackson E, Aiello NM, Haas NB, Rebbeck TR, Judkins A, Won KJ, Chodosh LA, Garcia BA, Stanger BZ, Feldman MD, Blair IA, Wellen KE.

Cell Metab. 2014 Aug 5;20(2):306-319. doi: 10.1016/j.cmet.2014.06.004. Epub 2014 Jul 3.


Adjuvant therapy for renal cell carcinoma: past, present, and future.

Pal SK, Haas NB.

Oncologist. 2014 Aug;19(8):851-9. doi: 10.1634/theoncologist.2014-0105. Epub 2014 Jun 26. Review.


A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.

Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB.

Oncologist. 2014 Apr;19(4):354-5. doi: 10.1634/theoncologist.2014-0020. Epub 2014 Mar 27.


Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.

Basch E, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, Higano CS, Harzstark AL, Sartor AO, Gordon MS, Vogelzang NJ, de Bono JS, Haas NB, Corn PG, Schimmoller F, Scher HI.

Eur Urol. 2015 Feb;67(2):310-8. doi: 10.1016/j.eururo.2014.02.013. Epub 2014 Feb 20.


Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas.

Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, Haas NB, Vaughn DJ, Lewis JD.

Diabetes Care. 2014 Jul;37(7):1910-7. doi: 10.2337/dc13-1489. Epub 2014 Feb 4.


Phase II trial of vorinostat in advanced melanoma.

Haas NB, Quirt I, Hotte S, McWhirter E, Polintan R, Litwin S, Adams PD, McBryan T, Wang L, Martin LP, vonMehren M, Alpaugh RK, Zweibel J, Oza A.

Invest New Drugs. 2014 Jun;32(3):526-34. doi: 10.1007/s10637-014-0066-9. Epub 2014 Jan 25.


Hereditary kidney cancer syndromes.

Haas NB, Nathanson KL.

Adv Chronic Kidney Dis. 2014 Jan;21(1):81-90. doi: 10.1053/j.ackd.2013.10.001. Review.


Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.

J Clin Oncol. 2013 Jan 10;31(2):181-6. doi: 10.1200/JCO.2012.43.3383. Epub 2012 Dec 3.


Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M.

J Clin Oncol. 2013 Feb 1;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.


Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.

Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1493-9. doi: 10.1016/j.ijrobp.2011.10.047. Epub 2012 Mar 6.


Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer.

Swisher-McClure S, Pollack CE, Christodouleas JP, Guzzo TJ, Haas NB, Vapiwala N, Bekelman JE.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):8-15. doi: 10.1016/j.ijrobp.2011.06.1951. Epub 2011 Nov 11.


Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment.

Yeboa DN, Guzzo T, Mitra N, Christodouleas JP, Haas NB, Vapiwala N, Armstrong K, Bekelman JE.

Urology. 2011 Nov;78(5):1107-13. doi: 10.1016/j.urology.2011.04.069. Epub 2011 Sep 23.


Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma.

Smaldone MC, Fung C, Uzzo RG, Haas NB.

Hematol Oncol Clin North Am. 2011 Aug;25(4):765-91. doi: 10.1016/j.hoc.2011.06.002. Review.


Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.

Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, von Mehren M, Grosh WW.

J Clin Oncol. 2011 Jul 20;29(21):2924-32. doi: 10.1200/JCO.2010.33.8053. Epub 2011 Jun 20.


Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.

Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM.

J Clin Oncol. 2011 May 20;29(15):2040-5. doi: 10.1200/JCO.2010.32.2776. Epub 2011 Apr 18.


A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.

Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J.

Med Oncol. 2012 Jun;29(2):761-7. doi: 10.1007/s12032-011-9829-8. Epub 2011 Feb 6.


Paired specimens: an opportunity to answer some important questions.

Haas NB.

Cancer. 2010 Feb 1;116(3):574-6. doi: 10.1002/cncr.24778. No abstract available.


Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.

Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA.

Clin Cancer Res. 2009 Nov 15;15(22):7036-44. doi: 10.1158/1078-0432.CCR-09-1544. Epub 2009 Nov 10.


Adjuvant therapy for renal cell carcinoma.

Haas NB, Uzzo R.

Curr Oncol Rep. 2008 May;10(3):245-52. Review.


Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer.

Uzzo RG, Haas NB, Crispen PL, Kolenko VM.

Cancer. 2008 Apr 15;112(8):1660-71. doi: 10.1002/cncr.23318. Review.


Targeted therapies for kidney cancer in urologic practice.

Haas NB, Uzzo RG.

Urol Oncol. 2007 Sep-Oct;25(5):420-32. Review.


Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer.

Haas NB, Uzzo RG.

Curr Treat Options Oncol. 2007 Jun;8(3):211-26. Review.


Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group.

Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G; Eastern Cooperative Oncology Group.

Cancer. 2007 Aug 15;110(4):759-63.


Adjuvant therapy for high-risk renal cell carcinoma patients.

Kunkle DA, Haas NB, Uzzo RG.

Curr Urol Rep. 2007 Jan;8(1):19-30. Review.



Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR, Martini M, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Thompson JA, Trisal V, Urist MM, Walker MJ; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Aug;4(7):666-84. No abstract available.


In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo.

Yao K, Gietema JA, Shida S, Selvakumaran M, Fonrose X, Haas NB, Testa J, O'Dwyer PJ.

Br J Cancer. 2005 Dec 12;93(12):1356-63.

Supplemental Content

Support Center